^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Roles of p53 and AXL Expressions on the Efficacy of ICI-Based Therapy in Patients with EGFR Mutated Lung Cancer after Osimertinib

Published date:
08/08/2023
Excerpt:
In patients with common EGFR mutations, high AXL expression was a predictor of shorter PFS and overall survival after ICI-based therapy (log-rank test; p = 0.04 and p = 0.02, respectively).
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

6222 / 24 - Clinical impact of p53 and AXL immunostaining on the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor mutant non-small cell lung cancer

Published date:
03/15/2023
Excerpt:
A total of 36 patients with advanced or recurrent EGFR-mutant NSCLC were analyzed. In multivariate analysis, p53 expression in tumors was an independent predictor of PFS after ICI-based therapy (p = 0.002). In patients with common EGFR mutations, high AXL expression was a predictor of shorter PFS and overall survival after ICI-based therapy (log-rank test; p = 0.04 and p = 0.02, respectively).